NEW YORK, Jan. 18 - Call off the florists.
Pharmacopeia and Eos Biotechnology said late on Thursday that their boards have mutually agreed to kill the planned merger they announced last August.
"We remain optimistic about the future prospects of the science, technology and people at Pharmacopeia," said Joseph Mollica, chairman, president and CEO of Pharmacopeia.
"We believe there are many ways in which we can prosper by adding to and leveraging our existing biology and chemistry capabilities. We will continue to pursue the many alternatives available to us," said Mollica.
David Martin, president and CEO of Eos, added: "Eos has the people, technology, partners and vision to build a leading therapeutic development company. We will continue to move forward aggressively with our plans for other therapeutic candidates and look to partner when appropriate."